• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.

作者信息

Boddy A V, Yule S M, Wyllie R, Price L, Pearson A D, Idle J R

机构信息

Department of Pharmacological Sciences, Medical School, University of Newcastle upon Tyne, Great Britain.

出版信息

Cancer Res. 1993 Aug 15;53(16):3758-64.

PMID:8339288
Abstract

The pharmacokinetics and metabolism of ifosfamide was investigated in a group of 16 pediatric patients (5 girls) aged 1-17 years. Each received a dose of 3 g/m2/day for up to 3 days by continuous infusion. Plasma and urine were collected, and concentrations of ifosfamide and its principal metabolites were determined by a quantitative high-performance thin layer chromatography method. During 3 days of continuous infusion, the plasma concentrations of parent drug decreased. This was accompanied by a continuous increase in dechloroethylated products in plasma but not in urine. Estimated pharmacokinetic parameters (clearance, volume of distribution, and half-life) were dependent on body size and age but not any other patient variable. Renal clearance was a relatively minor route of elimination for parent drug and corresponded to < 25% of glomerular filtration rate. Metabolite data from plasma and urine indicated a high degree of interindividual variation in metabolism. Comparison of metabolite recoveries in urine indicated a positive correlation between activation and inactivation routes of metabolism. Prior exposure to ifosfamide was associated with a higher recovery in urine of dechloroethylated metabolites. The severity of hematological toxicity was inversely correlated with glomerular filtration rate but not to parameters of ifosfamide metabolism. There was marked variation in levels of the carboxy metabolite, which could not be detected in the plasma of 5 subjects. However, evidence for a polymorphism in metabolism to this metabolite was weaker than that seen with the isomeric oxazaphosphorine cyclophosphamide. There appeared to be a higher clearance of ifosfamide in pediatric patients compared to adults. The significance of this, and of the variation in metabolism of ifosfamide, for clinical outcome remains to be established, but the increase in the dechloroethylation route of metabolism may be associated with an increased risk of toxicity.

摘要

相似文献

1
Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Cancer Res. 1993 Aug 15;53(16):3758-64.
2
Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.接受异环磷酰胺持续输注10天治疗的癌症患者血浆和尿液中异环磷酰胺、2-去氯乙基异环磷酰胺和3-去氯乙基异环磷酰胺的药代动力学
Anticancer Res. 1996 Sep-Oct;16(5B):3247-57.
3
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.剂量和输注持续时间对异环磷酰胺及其代谢产物药代动力学的影响。
Drug Metab Dispos. 2001 Jul;29(7):967-75.
4
Comparison of continuous infusion and bolus administration of ifosfamide in children.
Eur J Cancer. 1995;31A(5):785-90. doi: 10.1016/0959-8049(95)00090-6.
5
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
Cancer Chemother Pharmacol. 1995;36(1):53-60. doi: 10.1007/BF00685732.
6
Pharmacokinetics of ifosfamide and some metabolites in children.
Anticancer Res. 1998 May-Jun;18(3B):1941-9.
7
Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.
Anticancer Res. 1999 Jan-Feb;19(1B):837-42.
8
Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.异环磷酰胺肾毒性:儿科重复治疗期间代谢及给药方式的影响有限
Eur J Cancer. 1996 Jun;32A(7):1179-84. doi: 10.1016/0959-8049(96)00019-6.
9
Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.异环磷酰胺侧链代谢产物在持续和短期输注儿童中的排泄动力学
Int J Clin Pharmacol Ther. 1998 May;36(5):246-52.
10
Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
Eur J Cancer. 1995;31A(1):69-76. doi: 10.1016/0959-8049(94)00300-t.

引用本文的文献

1
Acute toxicity of chemotherapy in central nervous system germ cell tumour patients according to age.中枢神经系统生殖细胞瘤患者化疗的急性毒性与年龄的关系
Front Oncol. 2024 Jul 15;14:1421418. doi: 10.3389/fonc.2024.1421418. eCollection 2024.
2
Renal toxicity of ifosfamide in children with cancer: an exploratory study integrating aldehyde dehydrogenase enzymatic activity data and a wide-array urinary metabolomics approach.儿童癌症患者异环磷酰胺的肾毒性:整合醛脱氢酶酶活性数据和广泛的尿液代谢组学方法的探索性研究。
BMC Pediatr. 2024 Mar 19;24(1):196. doi: 10.1186/s12887-024-04633-1.
3
Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance.
新生儿和婴儿细胞毒药物的临床药理学:提供基于证据的剂量指导。
Eur J Cancer. 2022 Mar;164:137-154. doi: 10.1016/j.ejca.2021.11.001. Epub 2021 Dec 2.
4
Machine Learning Approach to Forecast Chemotherapy-Induced Haematological Toxicities in Patients with Rhabdomyosarcoma.预测横纹肌肉瘤患者化疗引起血液学毒性的机器学习方法
Cancers (Basel). 2020 Jul 17;12(7):1944. doi: 10.3390/cancers12071944.
5
A New Method to Quantify Ifosfamide Blood Levels Using Dried Blood Spots and UPLC-MS/MS in Paediatric Patients with Embryonic Solid Tumours.一种使用干血斑和超高效液相色谱-串联质谱法测定胚胎性实体瘤患儿异环磷酰胺血药浓度的新方法。
PLoS One. 2015 Nov 23;10(11):e0143421. doi: 10.1371/journal.pone.0143421. eCollection 2015.
6
Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma.14天持续输注异环磷酰胺方案治疗软组织肉瘤的临床活性及耐受性
Sarcoma. 2013;2013:868973. doi: 10.1155/2013/868973. Epub 2013 Dec 4.
7
Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.基于 UPLC-ESI-QTOFMS 的代谢组学研究在小鼠体内环磷酰胺和异环磷酰胺的比较代谢。
Biochem Pharmacol. 2010 Oct 1;80(7):1063-74. doi: 10.1016/j.bcp.2010.06.002. Epub 2010 Jun 10.
8
Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.异环磷酰胺的药代动力学和代谢与通过彗星试验评估的癌症患儿DNA损伤的关系。
Br J Cancer. 2005 May 9;92(9):1626-35. doi: 10.1038/sj.bjc.6602554.
9
Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.异环磷酰胺及其脱氯乙基化和羟基化代谢产物在恶性疾病儿童中的群体药代动力学:一种稀疏采样方法。
Clin Pharmacokinet. 2001;40(8):615-25. doi: 10.2165/00003088-200140080-00005.
10
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.异环磷酰胺及其代谢产物的临床药代动力学和药效学
Clin Pharmacokinet. 2001 Jan;40(1):41-62. doi: 10.2165/00003088-200140010-00004.